American Diabetes Association

Dr Robert Gabbay on Diabetes in the COVID-19 Era

June 30, 2020

Video

The coronavirus disease 2019 (COVID-19) pandemic will hopefully be a wakeup call to take diabetes more seriously and to work to prevent diabetes and its complications, said Robert Gabbay, MD, PhD, chief medical and scientific officer of the American Diabetes Association.

Dr Tara Kaushal Discusses Benefits of Active Technology Use as a Health Intervention for T1D

June 26, 2020

Video

Peer support is a huge advantage of technological health interventions for teens with type 1 diabetes (T1D), while integrating technology with physical activities is important when promoting healthy lifestyles, said Tara Kaushal, MD, physician and clinical researcher at Joslin Diabetes Center.

DPP Continues to Yield Positive Results, New DPPOS Data Show

June 17, 2020

Article

New results from the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association’s 80th Scientific Sessions, showed persistent reductions in type 2 diabetes (T2D) development over an average 22-year follow-up period.

DPP Continues to Yield Positive Results, New DPPOS Data Show

June 17, 2020

Article

New results from the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association’s 80th Scientific Sessions, showed persistent reductions in type 2 diabetes (T2D) development over an average 22-year follow-up period.

Are Newer Diabetes Drug Classes Ready for Prime Time in CV Prevention?

June 16, 2020

Article

The light-hearted debate, “Primary Cardiovascular Prevention with SGLT2 Inhibitors or GLP-1 Receptor Agonists: Are We Ready for Prime Time?” took place Monday during the 80th American Diabetes Association Scientific Sessions.

VERTIS CV: Ertugliflozin Falls Short of SGLT2s on CV Outcomes, Despite Promise in Heart Failure

June 16, 2020

Article

A finding that ertugliflozin produced a 30% drop in heart failure hospitalization risk fell outside the study’s primary and secondary end points; here, the drug performed within range of its class, the sodium glucose co-transporter 2 (SGLT2) inhibitors.

Dr Darren K. McGuire Discusses Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in T2D

June 16, 2020

Video

Many in the endocrinology community still endorse using metformin first in patients with type 2 diabetes, but that isn’t really necessary any more now that sodium-glucose transport protein 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are available, said Darren K. McGuire, MD, MHSc, professor of medicine in the Division of Cardiology, Dallas Heart Ball Chair for Research on Heart Disease in Women, Distinguished Teaching Professor, at the University of Texas Southwestern Medical Center.

Technology Roundup: CGM Systems, Joslin Home Featured at 2020 ADA Scientific Sessions

June 16, 2020

Article

Research presented at the American Diabetes Association's 80th Scientific Sessions offers new insights into the future of glycemic control, diabetes self-management, and remote care.

Starting Insulin, GLP-1 at Same Time Brings Better Glycemic Control, Real-World Data Show

June 15, 2020

Article

Selected abstracts from the American Diabetes Association's 80th Scientific Sessions discuss when to add injectable therapy, how patients who switched to semaglutide lost more weight and gained glycemic control, and offered results from an early-phase study on a monoclonal antibody that may preserve B-cell function.

COVID-19 Is Changing the A1C vs Time-in-Range Debate, Expert Says

June 15, 2020

Article

During a joint symposium on Saturday, held as part of the 80th American Diabetes Association Scientific Sessions and hosted by JDRF President and CEO Aaron Kowalski, PhD, experts debated the merits and pitfalls of how to measure glycemic control and overall health among persons with diabetes. Which is better, they asked: the traditional measure of glycated hemoglobin or the newer measure, time-in-range?